Biomerica (NASDAQ:BMRA) Shares Gap Up to $5.14
Biomerica, Inc. (NASDAQ:BMRA)’s share price gapped up before the market opened on Tuesday . The stock had previously closed at $5.14, but opened at $6.74. Biomerica shares last traded at $6.43, with a volume of 51,394 shares changing hands.
BMRA has been the topic of a number of research analyst reports. Colliers Securities initiated coverage on shares of Biomerica in a research report on Tuesday, November 10th. They set a “buy” rating and a $13.00 price objective on the stock. B. Riley decreased their price target on shares of Biomerica from $11.00 to $10.00 and set a “buy” rating on the stock in a research report on Tuesday. Finally, Aegis reduced their price objective on shares of Biomerica from $13.00 to $11.00 and set a “buy” rating for the company in a research note on Monday, October 19th.
The firm has a market capitalization of $73.69 million, a PE ratio of -19.59 and a beta of -0.47. The business’s 50 day simple moving average is $5.75 and its 200 day simple moving average is $7.05.
In other news, Director Catherine Coste bought 9,100 shares of the stock in a transaction dated Monday, October 26th. The stock was purchased at an average price of $5.45 per share, for a total transaction of $49,595.00. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. 23.70% of the stock is currently owned by company insiders.
Institutional investors have recently added to or reduced their stakes in the company. California Public Employees Retirement System bought a new position in shares of Biomerica during the 2nd quarter worth approximately $107,000. Squarepoint Ops LLC lifted its position in shares of Biomerica by 37.5% during the 3rd quarter. Squarepoint Ops LLC now owns 19,039 shares of the company’s stock worth $132,000 after buying an additional 5,197 shares in the last quarter. Finally, Emerald Advisers LLC bought a new position in shares of Biomerica during the 3rd quarter worth approximately $69,000. Hedge funds and other institutional investors own 15.52% of the company’s stock.
Biomerica Company Profile (NASDAQ:BMRA)
Biomerica, Inc, a biomedical technology company, together with its subsidiaries, develops, patents, manufactures, and markets diagnostic and therapeutic products or detection and/or treatment of medical conditions and diseases worldwide. The company's diagnostic test kits are used to analyze blood, urine, or fecal specimens from patients in the diagnosis of various diseases and other medical complications; or to measure the level of specific bacteria, hormones, antibodies, antigens, or other substances, which exist in the patient's body and stools or blood in extremely small concentrations.
Featured Article: What does EPS mean?
Receive News & Ratings for Biomerica Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Biomerica and related companies with MarketBeat.com's FREE daily email newsletter.